drugset / Trial / NCT07214142
Total Neoadjuvant Therapy With PD-1 for Locally Advcancer Rectal Cancer
Phase 2
Not yet recruiting
30 enrolled
The First Affiliated Hospital of University of Science and Technology of China
NaSingle-groupOpen-labelTreatment
Summary
Research Objective:To investigate the efficacy and safety of the "total neoadjuvant chemoradiotherapy combined with immunotherapy" regimen for the treatment of locally advanced rectal cancer with high-risk features for recurrence. Study Design:A single-arm, multicenter clinical study. Study Population: Patients with locally advanced rectal cancer presenting with high-risk features for local recurrence.
Timeline
- Start
- 2025-10-01
- Primary completion
- 2027-12-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |